

GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Ab-1

Catalog # MS-1170-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml)

Catalog # MS-1170-R7 (7.0ml)

Catalog # MS-1170-PCS

INTENDED USE:

- **For In Vitro Diagnostic Use:** This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy.
- **Description:** Gross cystic disease of the breast is benign premenopausal disorder in which cysts are a predominant pathological lesion. These cysts appear to be formed from excessive apocrine cystic secretions. This fluid is composed of several glycoproteins including a unique 15kDa monomer protein, Gross Cystic Disease Fluid Protein-15 (GCDFP15). Cytosolic analysis of normal tissue specimens from all major organs has demonstrated GCDFP15 in apocrine epithelia, lacrimal, ceruminous and Moll's glands and in numerous serous cells of the submandibular, tracheal, bronchial, sublingual and minor salivary glands. GCDFP15 and prostate specific antigen are co-expressed in androgen receptor-positive breast tumours.
- **Expected Staining Pattern:** Cytoplasmic
- **Positive Control:** Skin

MATERIALS PROVIDED:

GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Ab-1 (refer to catalog number):

- #MS-1170-S (or -S0, -S1): Tissue culture supernatant, concentrated, with 0.09% Sodium Azide.
or
- #MS-1170-R7: (7.0ml) of antibody prediluted in 0.05mol/L Tris-HCl, pH 7.6 containing stabilizing protein and 0.015mol/L sodium azide.
or
- #MS-1170-PCS: 5 positive control slides.
- **Antibody Concentration:** Not known
- **Host:** Mouse
- **Mol. Wt. of Antigen:** 15kDa
- **Species Reactivity:** Human and Rat. Others not-known.
- **Clone Designation:** 23A3
- **Ig Isotype / Light Chain:** IgG2a / kappa
- **Immunogen:** Recombinant protein encoding the excreted domain of human GCDFP15.
- **Microbiological State:** This product is not sterile.

MATERIALS REQUIRED, BUT NOT PROVIDED:

- **Antibody Diluent:** For concentrated antibodies, the antibody must be diluted before using. Use Lab Vision Antibody Diluent (catalog # TA-125-UD). Refer to diluent product instructions for use.
- **Negative Control Reagent:** Refer to the "General Protocol" instructions.
- **Visualization System:** Refer to the "General Protocol" instructions.

METHODS AND PROCEDURES:

Using UltraVision LP detection systems	
Specimen Preparation	Refer to the "General Protocol" instructions.
Dilution of Concentrated Antibody	1:30-1:60 in antibody diluent
Tissue Section Pretreatment	Staining of formalin-fixed tissue sections requires treating the tissue sections in boiling 10mM citrate buffer, pH 6.0 (Lab Vision catalog # AP-9003), for 10-20 minutes followed by cooling at room temperature for 20 min.
Primary Antibody Incubation Time	20 minutes at Room Temperature
Visualization	To detect antibody, follow the instructions provided with the visualization system.

GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Ab-1

Catalog # MS-1170-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml)

Catalog # MS-1170-R7 (7.0ml)

Catalog # MS-1170-PCS

Using UltraVision Quanto detection systems

Specimen Preparation	Refer to the "General Protocol" instructions.
Dilution of Concentrated Antibody	1:20 in antibody diluent
Tissue Section Pretreatment	Staining of formalin-fixed tissue sections requires treating the tissue sections in boiling 10mM citrate buffer, pH 6.0 (Lab Vision catalog # AP-9003), for 10-20 minutes followed by cooling at room temperature for 20 min.
Primary Antibody Incubation Time	20 minutes at Room Temperature
Visualization	To detect antibody, follow the instructions provided with the visualization system.

STORAGE and STABILITY:

This product contains sodium azide and is stable for 24 months when stored at 2-8°C. Do not use after expiration date indicated on label of the product. If reagent is not stored as recommended, performance must be validated by the user.

REFERENCES:

- 1) Hall R E, et al. British Journal of Cancer 78(3): 360-365 (1998).
- 2) Silloo B, et al. Modern Pathology. 11(11): 1033-1038 (1998).
- 3) Viacava P, et al. Virchows Arch. 432: 255-260 (1998).